Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Leveraging extracellular vesicle biology for novel tests and therapeutics for kidney fibrosis

Chiang CS., Kassianos AJ., Healy HG., Ng MSY.

Narrative Review on Chronic Kidney Disease, Chronic Inflammation, published in Clin Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Clin Transl Med (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42011979
PMCID
PMC13097387
DOI
10.1002/ctm2.70587

Abstract (original English)

Kidney fibrosis is mechanistically characterised by tissue injury followed by development of a fibrogenic niche. The fibrogenic niche involves chronic inflammation, vascular rarefaction, glomerulosclerosis, tubular atrophy, interstitial accumulation of extracellular matrix which replaces functional kidney parenchyma-culminating in reduced kidney function. Extracellular vesicles are bilipid membrane-encased nanoparticles that play critical roles as cell-to-cell messengers and waste management mechanisms. Extracellular vesciels communication has been demonstrated within the glomerulus, within the tubular compartment and, between tubular and glomerular compartments. Diverse extracellular vesicle cargoes interact with key pathways regulating cell facte and inflammation to mediate kidney fibrosis. Extracellular vesicles cargos can be leveraged as biomarkers to develop minimally invasive tests for kidney fibrosis and pinpoint active pathobiological processes to guide personalised mechanism-driven care. Mesechymal cell-derived extracellular vesicles, extracellular vesicles from bioengineered cells, post-modified extracellular vesicles and suppression of extracellular vesicle uptake have demonstrated promise in preclinical studies for preventing kidney fibrosis. Roadblocks to clinical implementation of extracellular vesicles as biomarkers include lack of standardised collection, measur

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
KidneyAnimalsHumansKidney DiseasesFibrosisBiomarkersExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research